A Phase 2 interventional study of OC-01 (varenicline) nasal spray 1.2 mg/ml and Placebo (vehicle) nasal spray in Neurotrophic Keratopathy, sponsored by Oyster Point Pharma, Inc.. Completed at 31 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-05-07.
Sponsored by Oyster Point Pharma, Inc. (part of Viatris Inc.) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The objective of this study is to evaluate the safety and effectiveness of OC-01 (varenicline) nasal spray as compared to placebo nasal spray for mean change from baseline in corneal fluorescein staining in subjects with Stage 1 (corneal epithelial hyperplasia/punctate keratopathy) neurotrophic keratopathy (NK) in one or both eyes.
Protocol OPP-102 is a Phase 2, multicenter, randomized, controlled, double- masked study designed to evaluate the safety and efficacy of OC-01 (varenicline) nasal spray in subjects with NK. Approximately 100 subjects at least 18 years of age with a physicians' diagnosis of Stage 1 NK as defined by the Mackie Criteria and meeting all other study eligibility criteria will be randomized 1:1 and will receive OC-01 (varenicline)/ nasal spray or placebo nasal spray for 8 weeks three times daily (TID) as follows:
Oyster Point Pharma, Inc. is the lead sponsor of 11 studies on the registry; none are open to participants now.
Of its 10 completed or terminated interventional studies of FDA-regulated products, 10 (100%) have results posted.
First submitted before Oyster Point Pharma, Inc. became part of Viatris Inc..
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GVHD (graft-versus-host disease)
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
OC-01 (varenicline) nasal spray, 1.2 mg/mL
Drug: OC-01 (varenicline) nasal spray 1.2 mg/ml
Placebo (vehicle control) nasal spray
Drug: Placebo (vehicle) nasal spray
Drug page: Varenicline
OC-01
Placebo (vehicle)
Mean Change From Baseline in Corneal Fluorescein Staining
Corneal Fluorescein Staining was measured utilizing the Modified Oxford Grading scale. Scores range from a minimum of 0 (no staining) to a maximum of 5. A higher score indicates a worse outcome. The study eye is defined as the eye with the worst staining grade (if both eyes are eligible).
Time frame: 8 weeks
Mean Change From Baseline in Visual Acuity at Week 8
Best Corrected Visual Acuity was assessed based on the number of letters read correctly on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart. ETDRS letters score range from 0 to 100 letters at each assessment. A higher score in ETDRS letters indicates a better outcome. A positive change from Baseline in ETDRS letter score indicates an improvement in visual acuity.
Time frame: 8 weeks
| Milestone | OC-01 (Varenicline) Nasal Spray, 1.2 mg/mL | Placebo (Vehicle Control) Nasal Spray |
|---|---|---|
| Started | 53 | 60 |
| Completed | 48 | 55 |
| Not completed | 5 | 5 |
| Withdrew: Adverse event | 1 | 0 |
| Withdrew: Lost to follow-up | 0 | 2 |
| Withdrew: Withdrawal by subject | 4 | 2 |
| Withdrew: Protocol violation | 0 | 1 |
Corneal Fluorescein Staining was measured utilizing the Modified Oxford Grading scale. Scores range from a minimum of 0 (no staining) to a maximum of 5. A higher score indicates a worse outcome. The study eye is defined as the eye with the worst staining grade (if both eyes are eligible).
| score on a scale | OC-01 (Varenicline) Nasal Spray, 1.2 mg/mL | Placebo (Vehicle Control) Nasal Spray |
|---|---|---|
| Mean Change From Baseline in Corneal Fluorescein Staining | -0.6 ± 0.17 | -0.9 ± 0.15 |
Best Corrected Visual Acuity was assessed based on the number of letters read correctly on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart. ETDRS letters score range from 0 to 100 letters at each assessment. A higher score in ETDRS letters indicates a better outcome. A positive change from Baseline in ETDRS letter score indicates an improvement in visual acuity.
| score on a scale | OC-01 (Varenicline) Nasal Spray, 1.2 mg/mL | Placebo (Vehicle Control) Nasal Spray |
|---|---|---|
| Mean Change From Baseline in Visual Acuity at Week 8 | 0.6 ± 1.15 | 1.5 ± 1.03 |
Collected over Adverse Events were collected at the time of informed consent until the last study visit at 6 months.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| OC-01 (Varenicline) Nasal Spray, 1.2 mg/mL | 0/54 (0%) | 5/54 (9.3%) | 39/54 (72.2%) |
| Placebo (Vehicle Control) Nasal Spray | 0/58 (0%) | 3/58 (5.2%) | 34/58 (58.6%) |
| Event | OC-01 (Varenicline) Nasal Spray, 1.2 mg/mL | Placebo (Vehicle Control) Nasal Spray |
|---|---|---|
| Infective Exacerbation of bronchiectasisInfections and infestations | 1/54 | 0/58 |
| PyelonephritisInfections and infestations | 1/54 | 0/58 |
| Skin InfectionInfections and infestations | 1/54 | 0/58 |
| Femur FractureInjury, poisoning and procedural complications | 1/54 | 0/58 |
| Renal NeoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/54 | 0/58 |
| Large Intestinal ObstructionGastrointestinal disorders | 0/54 | 1/58 |
| COVID-19Infections and infestations | 0/54 | 1/58 |
| FallInjury, poisoning and procedural complications | 0/54 | 1/58 |
| Event | OC-01 (Varenicline) Nasal Spray, 1.2 mg/mL | Placebo (Vehicle Control) Nasal Spray |
|---|---|---|
| SneezingRespiratory, thoracic and mediastinal disorders | 30/54 | 6/58 |
| Throat IrritationRespiratory, thoracic and mediastinal disorders | 6/54 | 0/58 |
| Nasal mucosal disorderRespiratory, thoracic and mediastinal disorders | 2/54 | 5/58 |
| Corneal epithelium defectEye disorders | 4/54 | 1/58 |
| Instillation Site IrritationGeneral disorders | 4/54 | 2/58 |
| Urinary Tract InfectionInfections and infestations | 3/54 | 2/58 |
| PainGeneral disorders | 0/54 | 3/58 |
| Eye IrritationEye disorders | 2/54 | 1/58 |
| Eye PainEye disorders | 2/54 | 1/58 |
| NauseaGastrointestinal disorders | 2/54 | 0/58 |
| Age, Continuous(years) | OC-01 (Varenicline) Nasal Spray, 1.2 mg/mL | Placebo (Vehicle Control) Nasal Spray | Total |
|---|---|---|---|
| Mean | 65.3 ± 14.48 | 61.5 ± 16.33 | 63.3 ± 15.54 |
| Sex: Female, Male(Participants) | OC-01 (Varenicline) Nasal Spray, 1.2 mg/mL | Placebo (Vehicle Control) Nasal Spray | Total |
|---|---|---|---|
| Female | 41 | 47 | 88 |
| Male | 12 | 13 | 25 |
| Ethnicity (NIH/OMB)(Participants) | OC-01 (Varenicline) Nasal Spray, 1.2 mg/mL | Placebo (Vehicle Control) Nasal Spray | Total |
|---|---|---|---|
| Hispanic or Latino | 9 | 14 | 23 |
| Not Hispanic or Latino | 44 | 45 | 89 |
| Unknown or Not Reported | 0 | 1 | 1 |
| Race (NIH/OMB)(Participants) | OC-01 (Varenicline) Nasal Spray, 1.2 mg/mL | Placebo (Vehicle Control) Nasal Spray | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 1 |
| Asian | 0 | 2 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 4 | 7 | 11 |
| White | 47 | 50 | 97 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 2 | 0 | 2 |
| Corneal Fluorescein staining Score(units on a scale) | OC-01 (Varenicline) Nasal Spray, 1.2 mg/mL | Placebo (Vehicle Control) Nasal Spray | Total |
|---|---|---|---|
| Mean | 2.29 ± 1.017 | 2.17 ± 1.028 | 2.23 ± 1.020 |
| Best Correct Visual Acuity (Letters)(Number of letters) | OC-01 (Varenicline) Nasal Spray, 1.2 mg/mL | Placebo (Vehicle Control) Nasal Spray | Total |
|---|---|---|---|
| Mean | 75.4 ± 14.42 | 75.9 ± 18.54 | 75.7 ± 16.61 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jun 2021 to primary completion in Jan 2023, 19 months.
Results were first posted in May 2024, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Varenicline